April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Candidate Biomarkers for the Detection of Severe Proliferative Vitreoretinopathy
Author Affiliations & Notes
  • F. Wang
    Ophthalmology, Shanghai First People's Hospital, Shanghai, China
  • J. Yu
    Ophthalmology, Shanghai First People's Hospital, Shanghai, China
  • T. Sun
    Ophthalmology, Shanghai First People's Hospital, Shanghai, China
  • Q. H. Qiu
    Ophthalmology, Shanghai First People's Hospital, Shanghai, China
  • L. Bai
    Ophthalmology, Shanghai First People's Hospital, Shanghai, China
  • H. Cao
    Ophthalmology, Shanghai First People's Hospital, Shanghai, China
  • Footnotes
    Commercial Relationships  F. Wang, None; J. Yu, None; T. Sun, None; Q.H. Qiu, None; L. Bai, None; H. Cao, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 6078. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Wang, J. Yu, T. Sun, Q. H. Qiu, L. Bai, H. Cao; Candidate Biomarkers for the Detection of Severe Proliferative Vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):6078.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We have recently reported that kininogen is a potential biomarker for proliferative vitreoretinopathy (PVR) (Yu et al 2008). In this study, we quantitatively evaluated the predictive potential of kininogen and insulin-like growth factor binding protein-6 (IGFBP-6) for severe PVR.

Methods: : Vitreous and serum samples were obtained from 24 PVR patients. Patients who underwent vitrectomy with silicone tamponade (n=8) and patients who experienced recurrent retinal detachment after scleral buckling surgery (n=8) were recruited for serum tests as well. Vitreous from 8 donated normal eyes, and serum samples from 20 healthy volunteers served as control. Western blot analysis was employed to detect the presence of kininogen and IGFBP-6. The protein concentration was measured by using ELISA analysis.

Results: : Although IGFBP-6 was absent in 2 PVR vitreous, both kininogen and IGFBP-6 were otherwise found in all PVR vitreous and serum samples. Neither kininogen nor IGFBP-6 can be detected in normal vitreous or serum samples. Protein expression was more intensive in severe PVR vitreous than in mild PVR vitreous, which was confirmed by a significantly higher concentration of each protein in sever PVR vitreous (table 1). Kininogen was about 2 times higher in serum than in vitreous; whereas IGFBP-6 was much lower in serum than in vitreous. Serum level of both proteins dropped significantly 6 months after PVR surgery, to a comparable level of patients underwent either vitrectomy with silicone tamponade or scleral buckling surgery.

Conclusions: : Kininogen and IGFBP-6 are presented in serum and vitreous in PVR patients. The strength of protein expression is related to the severity of PVR. These results suggested that kininogen and IGFBP-6 can be biomarkers for severe PVR.

Keywords: proliferative vitreoretinopathy • clinical (human) or epidemiologic studies: risk factor assessment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×